Status:
COMPLETED
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead Sponsor:
Amgen
Collaborating Sponsors:
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator
Innovative Therapies For Children with Cancer Consortium
Conditions:
Acute Lymphoblastic Leukemia (ALL)
Eligibility:
All Genders
1-21 years
Phase:
PHASE1
Brief Summary
The purpose of Phase 1b of this study is to: * Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractor...
Eligibility Criteria
Inclusion
- Phase 1b Key
- Age 21 years or younger at the time of initial ALL diagnosis and age \> 1 year at the time of study treatment initiation.
- Subjects must have a diagnosis of relapsed or refractory ALL with ≥ 5% blasts in the bone marrow (M2 or M3 disease), with or without extramedullary disease.
- To be eligible, subjects must have had 1 or more prior therapeutic attempts, defined as:
- Early first relapse (\< 36 months from original diagnosis) after achieving a CR (B-ALL) or first relapse any time following the original diagnosis after achieving a CR (T-ALL)
- First refractory bone marrow relapse occurring any time after original diagnosis after achieving a CR (ie, ≥1 failed attempt to induce a second remission) OR
- Relapse after achieving a CR following the first or subsequent relapse (i.e., ≥ 2 relapses) OR
- Failing to achieve a CR from original diagnosis after at least 1 induction attempt
- Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.
- Subjects must have a serum creatinine level that is ≤ 1.5 × institutional upper limit of normal (ULN) according to age. If serum creatinine level is \> 1.5 × ULN, the subject must have a calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m2.
- Adequate liver function, defined as both of the following:
- Total bilirubin ≤ 1.5 × institutional ULN except in the presence of Gilbert Syndrome
- Alanine aminotransferase (ALT) ≤ 5 × institutional ULN
- Performance status: Karnofsky or Lansky scores ≥ 50 for subjects \> 16 years old or ≤ 16 years old, respectively.
- Phase 2
- Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated, except for standard of care local testing as permitted per protocol.
- Age greater than or equal to 1 month to less than 21 years. Subjects greater than or equal to 18 years must have had their original diagnosis at less than 18 years of age.
- Subjects must be diagnosed with relapsed or refractory relapsed ALL.
- Subjects must have a documented first remission, less than 5% blasts in the bone marrow (M1 bone marrow) and no evidence of extramedullary disease.
- T-cell ALL with bone marrow relapse (defined as greater than or equal to 5% leukemia blasts in bone marrow) or refractory relapse with or without extramedullary disease.
- OR B-cell ALL bone marrow relapse or refractory relapse (defined as greater than or equal to 5% leukemia blasts in bone marrow) after having received a targeted B-cell immune therapy (eg, blinatumomab, inotuzumab or a CAR-T therapy) with or without extramedullary disease..
- Adequate liver function: bilirubin less than or equal to 1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) less than or equal to 5 x ULN.
- Adequate renal function: serum creatinine less than or equal to 1.5 x ULN or glomerular filtration rate (GFR) greater than or equal to 70 mL/min/1.73 m\^2; or for children less than 2 years of age, greater than or equal to 50 mL/min/1.73 m\^2.
- Adequate cardiac function: shortening fraction greater than or equal to 30% or ejection fraction greater than or equal to 50%.
- Karnofsky (subjects greater than or equal to 16 years of age) or Lansky (subjects 12 months to less than 16 years of age) performance status greater than or equal to 50%.
- Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment (for example: recovery from gastrointestinal toxicity may occur more rapidly than less reversible organ toxicities such as sinusoidal obstruction syndrome or non-infectious pneumonitis, for serious prior toxicities recommended discussion with Amgen medical monitor).
- Life expectancy of greater than 6 weeks per investigator's judgement at time of screening.
- Phase 1b Key
Exclusion
- Known allergy to any of the drugs used in the study (Subjects who have had a previous allergy to PEG-asparaginase and if able, may receive Erwinia asparaginase at the investigator's discretion)
- Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
- Left ventricular fractional shortening \< 30%
- History of ≥ Grade 2 pancreatitis
- Active graft-versus-host disease requiring systemic treatment
- Positive culture for or other clinical evidence of infection with bacteria or fungus within 14 days of the initiation of study treatment
- Down Syndrome
- Prior therapy restrictions:
- Subjects must have completed therapy with granulocyte-colony stimulating factor (G-CSF) or other myeloid growth factors at least 7 days before study treatment initiation, or at least 14 days before study treatment initiation, if pegylated myeloid growth factors were administered.
- Subjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.
- Subjects must have received the last dose of a non-monoclonal antibody biologic agent at least 7 days before study treatment initiation.
- At least 3 antibody half-lives must have elapsed since the last dose of monoclonal antibody (e.g., 66 days for rituximab and 69 days for epratuzumab) before subjects may initiate study treatment.
- Subjects must not have received other antineoplastic agents with therapeutic intent, excluding hydroxyurea and antimetabolites administered as part of maintenance chemotherapy, within 7 days prior to study treatment initiation.
- Hepatitis B infection with positive hepatitis B DNA
- Phase 2
Key Trial Info
Start Date :
February 16 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2024
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT02303821
Start Date
February 16 2015
End Date
June 28 2024
Last Update
June 4 2025
Active Locations (122)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco Benioff Childrens Hospital Oakland
Oakland, California, United States, 94609
2
Childrens Hospital of Orange County
Orange, California, United States, 92868
3
Childrens Hospital Colorado
Aurora, Colorado, United States, 80045
4
Childrens Healthcare of Atlanta, Egleston
Atlanta, Georgia, United States, 30322